A Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Oral Sodium Fusidate (CEM-102) Compared to Oral Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infections

Trial Profile

A Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Oral Sodium Fusidate (CEM-102) Compared to Oral Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infections

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Fusidic acid (Primary) ; Linezolid
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Cempra Pharmaceuticals
  • Most Recent Events

    • 02 Jun 2017 According to a Cempra Pharmaceuticals media release, data will be presented at the American Society for Microbiology (ASM) 2017 meeting.
    • 28 Mar 2017 Status changed from active, no longer recruiting to completed, according to a Cempra Inc. media release.
    • 24 Feb 2017 Results published in the Cempra Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top